Voyager Therapeutics (NASDAQ:VYGR) Stock Rating Upgraded by StockNews.com

by · The Cerbat Gem

StockNews.com upgraded shares of Voyager Therapeutics (NASDAQ:VYGR – Free Report) from a hold rating to a buy rating in a report released on Saturday.

VYGR has been the topic of several other reports. Leerink Partners began coverage on shares of Voyager Therapeutics in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price target on the stock. Wedbush decreased their target price on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, October 24th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Voyager Therapeutics presently has an average rating of “Buy” and a consensus price target of $17.43.

Read Our Latest Research Report on VYGR

Voyager Therapeutics Price Performance

NASDAQ VYGR opened at $6.65 on Friday. The stock’s 50 day simple moving average is $6.56 and its 200-day simple moving average is $7.55. The company has a market cap of $362.64 million, a PE ratio of 23.75 and a beta of 0.89. Voyager Therapeutics has a 1-year low of $5.71 and a 1-year high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.20. Voyager Therapeutics had a return on equity of 3.31% and a net margin of 6.28%. The company had revenue of $29.58 million for the quarter, compared to analyst estimates of $11.52 million. During the same quarter last year, the firm posted ($0.51) EPS. On average, equities research analysts anticipate that Voyager Therapeutics will post -1.27 EPS for the current fiscal year.

Insider Activity

In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the completion of the transaction, the insider now directly owns 86,001 shares in the company, valued at approximately $500,525.82. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 4.53% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. raised its stake in shares of Voyager Therapeutics by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock valued at $61,000 after acquiring an additional 4,098 shares during the period. Patriot Financial Group Insurance Agency LLC grew its position in Voyager Therapeutics by 7.0% in the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 136,894 shares of the company’s stock valued at $801,000 after acquiring an additional 9,000 shares in the last quarter. Hunter Perkins Capital Management LLC lifted its position in shares of Voyager Therapeutics by 3.3% during the third quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company’s stock worth $375,000 after purchasing an additional 2,025 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Voyager Therapeutics by 6.0% in the second quarter. The Manufacturers Life Insurance Company now owns 94,398 shares of the company’s stock valued at $747,000 after purchasing an additional 5,365 shares in the last quarter. Finally, Armistice Capital LLC increased its stake in Voyager Therapeutics by 11.3% during the 2nd quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock worth $41,132,000 after buying an additional 528,000 shares during the period. Hedge funds and other institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

(Get Free Report)

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.

Read More